Sanofi India has strongly refuted a recent report claiming the company has initiated the sale or licensing of its flagship insulin brand, Lantus. In a stock exchange filing, Sanofi India said ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Mumbai: Sanofi India has started the process of selling its flagship insulin brand, Lantus, with major domestic pharmaceutical companies such as Glenmark, Dr. Reddy's Laboratories, and Emcure Pharma ...

Types of insulin include rapid-, regular-, intermediate-, and long-acting, based on how long they take to start working. You may take a combination of these when managing type 2 diabetes. If you ...

Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood. When ...